Loading stock data…
Design Therapeutics (DSGN)
$14.24+0.89 (+6.67%)
Market ClosedLast close Jun 29
Design Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Design Therapeutics, Inc. in the Healthcare sector is trading at $14.24 with a market capitalization of $656M. Wall Street consensus targets $21.00 (6 analysts), implying a +47.5% move over the next 12 months. The stock is currently 17% below its 52-week high of $17.25, remaining 45.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +47.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.71M↓ | -$18.17M↑ | -$19.31M↑ | -$21.57M↓ | -$20.42M |
| Net Income | -$17.64M↓ | -$16.00M↑ | -$17.00M↑ | -$19.08M↓ | -$17.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platfo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$656.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.97%
Volume
Today's trading volume
1.46M
Recent News
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
This Biotech Leader Ran Up As Much As 18% — And Then Lost It All
Design Therapeutics shares ran up early Monday on positive results in Friedreich's ataxia. And then, the biotech stock lost it all.
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)
Stock Surges Following Positive Clinical UpdateShares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the company released favorable four-week data from its RESTORE-FA clinical trial evaluating DT-216P2 in patients with Friedreich ataxia. The biotechnology company said the treatment produced dose-dependent improvements across several clinical measurements while also increasing endogenous frataxin mRNA and protein levels after four weeks of intravenous administration.
Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec”
Design Therapeutics, Inc. (NASDAQ:DSGN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise caution when it comes to red-hot AI stocks. A caller asked for Cramer’s thoughts on the company, and here’s what he had to say: Pure spec, pure spec. Understand, you can lose everything, or you can double […]
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.